Medline (NASDAQ:MDLN) Stock Price Expected to Rise, Citigroup Analyst Says

Medline (NASDAQ:MDLN) had its price objective lifted by analysts at Citigroup from $48.00 to $60.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price objective points to a potential upside of 26.29% from the stock’s current price.

Several other equities research analysts have also issued reports on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medline in a research note on Monday, January 12th. They issued a “hold” rating and a $40.00 price target on the stock. Mizuho initiated coverage on Medline in a research report on Monday, January 12th. They issued an “outperform” rating and a $48.00 target price on the stock. BNP Paribas Exane assumed coverage on Medline in a research report on Monday, January 12th. They set a “neutral” rating and a $38.00 price target for the company. Royal Bank Of Canada raised their price target on Medline from $47.00 to $53.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Robert W. Baird started coverage on Medline in a research note on Monday, January 12th. They set an “outperform” rating and a $48.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $50.35.

Medline Trading Down 2.8%

NASDAQ MDLN opened at $47.51 on Thursday. Medline has a 52 week low of $34.89 and a 52 week high of $50.88. The company has a 50 day moving average price of $44.52.

Medline (NASDAQ:MDLN) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.25). The firm had revenue of $7.79 billion for the quarter, compared to the consensus estimate of $7.52 billion. The business’s quarterly revenue was up 14.8% compared to the same quarter last year.

Insiders Place Their Bets

In other Medline news, Director Charles N. Mills acquired 2,579,310 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were purchased at an average price of $29.00 per share, for a total transaction of $74,799,990.00. Following the completion of the purchase, the director directly owned 2,441,379 shares of the company’s stock, valued at approximately $70,799,991. This represents a -1,870.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Andrew J. Mills acquired 2,586,206 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was acquired at an average cost of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the transaction, the director owned 2,586,206 shares of the company’s stock, valued at approximately $74,999,974. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Hedge Funds Weigh In On Medline

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Carlyle Group Inc. acquired a new position in shares of Medline in the fourth quarter valued at $9,042,728,000. H&F Corporate Investors X Ltd. bought a new stake in shares of Medline during the 4th quarter worth about $4,179,591,000. Vanguard Group Inc. bought a new stake in shares of Medline during the 4th quarter worth about $793,278,000. Morgan Stanley acquired a new position in Medline in the 4th quarter valued at about $636,807,000. Finally, Capital Research Global Investors bought a new position in Medline in the 4th quarter valued at about $620,937,000.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Citigroup raised its price target to $60 and kept a “buy” rating — a ~26.6% upside from the recent price, highlighting conviction after the quarter. Citigroup Raise
• Positive Sentiment: UBS increased its target to $57 and maintained a “buy” rating — ~20.2% upside — reflecting upgraded forecasts post-Q4. UBS Raise
• Positive Sentiment: BMO lifted its target to $54 and set an “outperform” rating (~13.9% upside), joining other brokers in boosting estimates after the quarter. BMO Raise
• Positive Sentiment: RBC raised its target to $53 with an “outperform” call (~11.8% upside), another vote of confidence from the street. RBC Raise
• Neutral Sentiment: Analysts broadly boosted forecasts after Q4 results; summary coverage aggregates the upgrades and modeling adjustments. Analysts Boost Forecasts
• Neutral Sentiment: Medline’s Q4 earnings call highlighted record sales and strategic innovations — supportive for revenue trajectory but mixed vs. EPS expectations. Earnings Call Highlights
• Neutral Sentiment: Full earnings call transcript is available for investors who want detail on guidance, margin commentary and management tone. Earnings Transcript
• Neutral Sentiment: Wells Fargo raised its target slightly to $47 but kept an “equal weight” rating — effectively neutral near-term guidance from this shop. Wells Fargo Note
• Negative Sentiment: Shares gapped down after what coverage labels a weak earnings print (EPS miss despite a revenue beat), which prompted the initial selloff. Shares Gap Down
• Negative Sentiment: As Medline transitions to public markets, the IPO/ESOP disclosures and management’s growth guidance drew public scrutiny — a source of near-term uncertainty for investors. IPO Scrutiny

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.